Chris Shibutani, Goldman Sachs anlayst, joins ‘Squawk on the Street’ to discuss what gives the analyst the confidence Eli Lilly and Novo Nordisk can continue to perform, what happens to the anti-obesity industry in 2030, and how the market will evolve.
